Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Phase 1

Active, not recruiting

• Conditions: Multiple Myeloma
• Interventions: Biological: zevor-cel

• Registration Number: NCT03915184
• Lead Sponsor: CARsgen Therapeutics Co., Ltd.

Brief Summary

A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.

Detailed Description

This is an open label, multi-center, phase 1b/2 clinical trial to evaluate the safety and efficacy of autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell; zevor-cel/CT053) in patients with relapsed and or refractory multiple myeloma.

Phase 1b of the study will be dose escalation followed by an expansion cohort. After recommended Phase 2 dose is identified in Phase 1b, the enrollment of Phase 2 will start. Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (zevor-cel). Following manufacture of the drug product, subjects will receive lymphodepletion prior to zevor-cel infusion. All subjects who complete the study, as well as those who withdraw from the study after receiving zevor-cel for reasons other than death or meeting the early termination criteria, will be asked to continue to undergo a 15-year long-term follow-up study.

Study Timeline

• Study First Submitted: 2019-04-03
• Study First Submitted QC: 2019-04-12
• Study First Posted: 2019-04-16
• Study Start: 2019-09-25
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-18
• Last Update Posted: 2023-12-19
• Primary Completion: 2024-12-31
• Study Completion: 2034-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 105

Inclusion Criteria

1. Voluntarily signed consent;
2. Age of ≥ 18 and < 80 years;
3. Received sufficient prior lines of myeloma therapy;
4. Received treatment with at least one proteasome inhibitor, one IMiD and CD38 anti body.
5. The patient must be refractory to the last line of therapy.
6. The patients should have measurable disease per IMWG definition.
7. Estimated life expectancy > 12 weeks;
8. ECOG performance score 0-1;
9. Patients should have reasonable CBC counts, renal and hepatic functions;
10. Sufficient venous access for leukapheresis collection, and no other contraindications to leukapheresis;
11. Women of childbearing age must undergo a serum pregnancy test with negative results before screening, and are willing to use effective and reliable method of contraception for at least 12 months after T cell infusion;
12. Men must be willing to use effective and reliable method of contraception for at least 12 months after T cell infusion.

Exclusion Criteria

1. Pregnant or lactating women;
2. HIV, active hepatitis C virus (HCV), or active hepatitis B virus (HBV) infection;
3. Any uncontrolled active infection;
4. AEs from previous treatment that have not recovered;
5. Patients who have had anti-BCMA therapy;
6. Patients who have graft versus host disease (GvHD);
7. Patients have received stem cell transplantation one year before leukapheresis;
8. Patients have received any anti-cancer treatment before leukapheresis;
9. Patients have received steroids before leukapheresis or lymphodepletion;
10. Patients have plasma cell leukemia, Waldenström macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome or clinically significant symptomatic immunoglobulin light chain (AL) amyloidosis with evidence of end-organ damage;
11. Patients have been administered live attenuated vaccine before leukapheresis or lymphodepletion;
12. Patients allergic to Flu, Cy, tocilizumab, dimethyl sulfoxide (DMSO) or zevor-cel CAR BCMA T cell;
13. Patients have clinical significant cardiac conditions that researchers believe that participating in this clinical trial may endanger the health of the patients;
14. Patients have clinical significant pulmonary conditions;
15. Patients are known to have active autoimmune diseases including but not limited to psoriasis, rheumatoid arthritis and other needs of long-term immunosuppressive therapy;
16. Patients with second malignancies in addition to MM are not eligible;
17. Patients have central nervous system (CNS) metastases or CNS involvement;
18. Patients have significant neurologic disorders;
19. Patients are unable or unwilling to comply with the requirements of clinical trial;
20. Patients have received major surgery prior to leukapheresis or prior to lymphodepletion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
CAR-BCMA T Cells	zevor-cel	Phase 1b will include a dose escalation followed by an expansion cohort to determine the recommended dose for the expansion part. After recommended Phase 2 is determined, patients in Phase 2 will be treated.

Primary Outcome Measures

Name	Time	Method
Objective response rate	Day 1 - Month 60	Objective response rate (ORR) per IMWG by IRC read
Incidence of Treatment Related adverse events (AEs)	Day 1 - Month 60	Incidence of Treatment Related AEs, AEs of special interest and serious adverse events (SAEs)
Identification of Maximum Tolerated Dose (MTD)	Day 1 - Month 60	Incidence of dose-limiting toxicities (DLTs)

Secondary Outcome Measures

Name	Time	Method
Evaluate utilization of hospital resources	Day 1 - Month 60	Duration of hospitalization and ICU
Evaluate zevor-cel PK profile	Day 1 - Month 60	CAR transgene copy number, peak value, AUC, in vivo persistence
Evaluate HRQoL in patients with rrMM from baseline up to study completion	Day 1 - Month 60	Change from baseline in HRQoL as measured by EORTC QLQ-C30 and QLQ-MY20
Evaluate additional clinical efficacy outcomes with zevor-cel treatment in patients with rrMM	Day 1 - Month 60	Disease-specific response criteria including, but not limited to: complete response (CR), MRD, very good partial response (VGPR), and partial response (PR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma, Time to Response, Time to Progression, Progression Free Survival, best response and Overall Survival
Determine the efficacy of zevor-cel treatment in patients with rrMM, by investigator assessment	Day 1 - Month 60	ORR, DOR, FPS, OS, MRD, time to response, time to progression, best tumor response
Evaluate ADA profile	Day 1 - Month 60	Percentage of patients with anti-zevor-cel drug antibodies

Trial Locations

Locations (13)

Moffitt Cancer Center; 🇺🇸 Tampa, Florida, United States

Mayo Clinic Hospital; 🇺🇸 Phoenix, Arizona, United States

Colorado Blood Cancer Institute; 🇺🇸 Denver, Colorado, United States

TriStar CMC; 🇺🇸 Nashville, Tennessee, United States

Mayo; 🇺🇸 Rochester, Minnesota, United States

Medical College of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States

MD Anderson; 🇺🇸 Houston, Texas, United States

Methodist Hosptial; 🇺🇸 Houston, Texas, United States

Dana Farber Cancer Center; 🇺🇸 Boston, Massachusetts, United States

Huntsman Cancer Center; 🇺🇸 Salt Lake City, Utah, United States

UT Southwestern Medical Center; 🇺🇸 Dallas, Texas, United States

Princess Margaret Hospital; 🇨🇦 Toronto, Ontario, Canada

UCSF; 🇺🇸 San Francisco, California, United States